Can you provide the last earnings date for KINIKSA PHARMACEUTICALS INTE?
KINIKSA PHARMACEUTICALS INTE (KNSA) last reported earnings on 2/24/2026.
KINIKSA PHARMACEUTICALS INTE (KNSA) Earnings History & Surprises
NASDAQ:KNSA • GB00BRXB0C07
Current stock price
45.78 USD
-0.29 (-0.63%)
At close:
45.78 USD
0 (0%)
After Hours:
KNSA Earnings overview
Past quarterly earnings results for KINIKSA PHARMACEUTICALS INTE (KNSA), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- Apr 21, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $0.29
- Revenue Estimate
- 211.4M
Last Reported
Most Recent- Release Date
- Feb 24, 2026
- Period
- Q4 / 2025
- EPS Reported
- $0.17
- EPS Surprise
- -55.48%
- Revenue Surprise
- 1.62%
Beat Rate
Last 8 Quarters 50%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 0.17 | 0.38 | -55.48% | 241.67% | 202.127M | 198.91M | 1.62% | 64.95% |
| Q3 2025 | 0.23 | 0.33 | -30.25% | 227.78% | 180.855M | 170.71M | 5.94% | 61.17% |
| Q2 2025 | 0.23 | 0.19 | 23.78% | 483.33% | 156.797M | 149.35M | 4.99% | 51.65% |
| Q1 2025 | 0.11 | 0.04 | 156.77% | 144.00% | 137.785M | 133.07M | 3.54% | 72.54% |
| Q4 2024 | -0.12 | 0.00 | -5,782.35% | -134.29% | 122.536M | 125.84M | -2.63% | 46.93% |
| Q3 2024 | -0.18 | 0.03 | -651.47% | 10.00% | 112.214M | 113.75M | -1.35% | 67.37% |
| Q2 2024 | -0.06 | -0.08 | 21.57% | -128.57% | 103.391M | 94.159M | 9.80% | 44.66% |
| Q1 2024 | -0.25 | -0.17 | -50.06% | -38.89% | 79.858M | 80.029M | -0.21% | 65.18% |
| Q4 2023 | 0.35 | -0.14 | 345.10% | 483.33% | 83.395M | 73.459M | 13.53% | 34.76% |
| Q3 2023 | -0.20 | -0.17 | -17.06% | -106.29% | 67.046M | 65.736M | 1.99% | -32.37% |
| Q2 2023 | 0.21 | -0.17 | 222.91% | 172.41% | 71.473M | 53.24M | 34.25% | 164.99% |
| Q1 2023 | -0.18 | -0.21 | 14.95% | 50.00% | 48.345M | 47.508M | 1.76% | 50.19% |
| Q4 2022 | 0.06 | -0.24 | 125.30% | 111.32% | 61.884M | 46.018M | 34.48% | 230.14% |
| Q3 2022 | 3.18 | 0.80 | 298.42% | 822.73% | 99.135M | 95.516M | 3.79% | 719.64% |
| Q2 2022 | -0.29 | -0.45 | 35.75% | 52.46% | 26.972M | 29.124M | -7.39% | 250.10% |
| Q1 2022 | -0.36 | -0.41 | 13.21% | 50.00% | 32.189M | 23.226M | 38.59% | - |
| Q4 2021 | -0.53 | -0.43 | -23.72% | 32.91% | 18.745M | 21.139M | -11.33% | - |
| Q3 2021 | -0.44 | -0.66 | 33.38% | 33.33% | 12.095M | 10.38M | 16.52% | - |
| Q2 2021 | -0.61 | -0.81 | 24.54% | 6.15% | 7.704M | 4.048M | 90.32% | - |
| Q1 2021 | -0.72 | -0.74 | 2.64% | -50.00% | 7.931M | -100.00% | - | |
| Q4 2020 | -0.79 | -0.63 | -24.42% | - | - | - | ||
| Q3 2020 | -0.66 | -0.62 | -6.95% | - | - | - | ||
| Q2 2020 | -0.65 | -0.64 | -1.80% | - | - | - | ||
| Q1 2020 | -0.48 | -0.65 | 25.77% | - | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
23.70%
Max EPS beat (4)
156.77%
Min EPS beat (4)
-55.48%
Revenue beat statistics
Revenue beat (4)
4
Average Revenue beat (4)
4.02%
Max Revenue beat (4)
5.94%
Min Revenue beat (4)
1.62%
Analysis
In the last 4 quarters, KNSA has beaten EPS estimates in 2 out of 4 releases
KNSA has consistently beaten revenue estimates in all past 4 earnings releases
In the last 4 quarters, KNSA has beaten the EPS estimates by 23.7% on average.
In the last 4 quarters, KNSA has beaten the revenue estimates by 4.0% on average.
Related analysis
KINIKSA PHARMACEUTICALS INTE / KNSA Earnings FAQ
Can you provide information on whether KINIKSA PHARMACEUTICALS INTE beat earnings estimates in the last quarter?
KINIKSA PHARMACEUTICALS INTE (KNSA) missed EPS estimates and beat revenue estimates in the most recent quarter.
Can you provide information on how often KINIKSA PHARMACEUTICALS INTE beats earnings estimates?
In the last 4 quarters, KINIKSA PHARMACEUTICALS INTE (KNSA) has beaten EPS estimates in 2 out of 4 releases.